Guanabenz

CHEMBL420 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
231.1 g/mol
LogP
1.7
Phase
4

A centrally acting alpha-2 adrenergic agonist used to treat hypertension by reducing sympathetic nervous system outflow from the brain, which lowers heart rate and relaxes blood vessels. It is taken orally and was used before newer antihypertensive agents became available. Abrupt discontinuation can cause rebound hypertension and should be avoided.

分子量

231.0800 g/mol

LogP

1.70

TPSA

76.80 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N=C(N)N/N=C/c1c(Cl)cccc1Cl

InChI

InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+

Molecular Formula

C8H8Cl2N4

HBD / HBA

2 / 2

回転可能結合数

2

重原子数

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A centrally acting alpha-2 adrenergic agonist used to treat hypertension by reducing sympathetic nervous system outflow from the brain, which lowers heart rate and relaxes blood vessels. It is taken orally and was used before newer antihypertensive agents became available. Abrupt discontinuation can cause rebound hypertension and should be avoided.

Yes, Guanabenz is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL420. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5702063. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.